Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/11/2021 | 04:05pm EST

OpGen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 1.24 million compared to USD 1.06 million a year ago. Net loss was USD 6.06 million compared to USD 7.68 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.4 a year ago. For the nine months, revenue was USD 2.88 million compared to USD 2.86 million a year ago. Net loss was USD 27.99 million compared to USD 19.1 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 1.36 a year ago.


ę S&P Capital IQ 2021
All news about OPGEN, INC.
01/10OPGEN : Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Upda..
PU
01/10OPGEN : Corporate Presentation (PDF)
PU
2021Opgen Subsidiary Ares Genetics Announces the Strategic Expansion of Aresdb Proprietary ..
CI
2021OPGEN : Announces Results of Special Meeting of Stockholders - Form 8-K
PU
2021OPGEN INC : Submission of Matters to a Vote of Security Holders, Other Events, Financial S..
AQ
2021OpGen Announces Results of Special Meeting of Stockholders
AQ
2021OPGEN : Corporate Presentation (PDF)
PU
2021OPGEN : Subsidiary Ares Genetics Announces Strategic Database Access Transaction - Form 8-..
PU
2021OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction
GL
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 4,29 M - -
Net income 2021 -35,6 M - -
Net cash 2021 8,88 M - -
P/E ratio 2021 -1,01x
Yield 2021 -
Capitalization 45,6 M 45,6 M -
EV / Sales 2021 8,55x
EV / Sales 2022 7,32x
Nbr of Employees 102
Free-Float 99,7%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,98 $
Average target price 3,50 $
Spread / Average Target 257%
EPS Revisions
Managers and Directors
Oliver Schacht President, Chief Executive Officer & Director
Albert Weber Chief Financial Officer
William E. Rhodes Non-Executive Chairman
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-2.01%46
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684